General Information of Drug (ID: DMNHPOT)

Drug Name
LErafAON Drug Info
Synonyms
RafAON; Antisense raf oligonucleotide, NeoPharm; LErafAON, Insys; LErafAON-ETU; Liposomal antisense therapy, NeoPharm; Cancer therapeutic (antisense), NeoPharm; Liposome encapsulated c-raf antisense oligodeoxynucleotide, NeoPharm; Antisense oligonucleotides (liposome-encapsulated), NeoPharm
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMNHPOT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MLN2480 DMBR8NF Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
RG7304 DMGFAVQ Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
SPN-803 DM8O2AQ Parkinson disease 8A00.0 Phase 1 [3]
LXH254 DMQE9PS Non-small-cell lung cancer 2C25.Y Phase 1 [5]
ICo-007 DM79W8K Diabetic macular edema 9B71.02 Phase 1 [6]
DEBROMOHYMENIALDISINE DMDLER8 Discovery agent N.A. Investigative [7]
ZM-336372 DMD5JYQ Discovery agent N.A. Investigative [8]
6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine DMDNG8F Discovery agent N.A. Investigative [9]
PLX-ORI3 DMZG1L5 Solid tumour/cancer 2A00-2F9Z Investigative [3]
6-Benzylsulfanyl-9H-purine DMI7FNZ Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Raf messenger RNA (Raf mRNA) TTAN5W2 RAF1_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT00100672) Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer. U.S. National Institutes of Health.
2 Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs. 2004 Mar;15(3):243-53.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184).
4 Clinical pipeline report, company report or official report of Roche.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
7 Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32.
8 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
9 Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.